- This event has passed.
BioScience Forum Presents: Precision CRISPR Therapies
BioScience Forum Presents: Precision CRISPR Therapies
Advances in biotechnology are transforming the future of medicine, and one of the most exciting breakthroughs in recent years is the development of CRISPR-based therapies. Scientists around the world are exploring how genome editing can be used to treat complex diseases that previously had limited treatment options.
The upcoming BioScience Forum Presents: Precision CRISPR Therapies offers a unique opportunity for professionals, researchers, and science enthusiasts to learn about the latest progress in this revolutionary field. The event will feature insights from Aarif Khakoo, who will discuss how Scribe Therapeutics is applying advanced genome-editing technology to develop therapies for cardiometabolic diseases.
The forum will take place at The Alexandria at San Carlos, bringing together members of the regional bioscience community for an evening of learning, networking, and scientific discovery.
Precision CRISPR Therapies: Targeting Cardiometabolic Pathways
The focus of the event is the cutting-edge topic “Precision CRISPR Therapies: Targeting Cardiometabolic Pathways with In Vivo Genome Editing.”
Developing effective therapeutics requires optimizing several critical factors, including potency, specificity, and deliverability. These factors are especially important when using genome-editing technologies like CRISPR gene editing, which allow scientists to make precise changes to DNA within living organisms.
Scribe Therapeutics has developed a strategy known as CRISPR by Design™, an innovative approach that carefully engineers CRISPR tools to maximize safety and effectiveness. This strategy supports the company’s internal research programs targeting cardiometabolic diseases, while also contributing to collaborations focused on neurological, neuromuscular, and genetic conditions such as Sickle Cell Disease.
A New Starting Point: CasX
A key innovation behind Scribe’s work is its use of CasX, a novel CRISPR enzyme.
CasX offers several advantages compared to other genome-editing systems. It is relatively compact, easier to deliver into cells, and potentially safer. By using this enzyme as the foundation for their research, Scribe scientists have engineered powerful platforms designed to address genetic diseases more effectively.
These technologies aim to set new standards for genetic medicine, opening doors to treatments that target the root causes of disease rather than only managing symptoms.
Two Powerful Platforms: ELXR and XE
Scribe has created two groundbreaking platforms designed to deliver precision therapies.
The first platform is ELXR, which stands for Epigenetic Long-Term X-Repressor. This technology allows scientists to silence specific genes without cutting the DNA itself. Instead of editing the genetic code directly, ELXR modifies how genes are expressed, providing a safer method of controlling harmful genetic activity.
The second platform is XE, or X-Editor, which enables direct gene editing with extremely high precision. One of its most promising features is the absence of detectable off-target editing, meaning it can modify target genes without unintentionally affecting other parts of the genome.
Together, these platforms represent an important step toward developing highly targeted and reliable gene therapies.
The STX-1150 Program
One of Scribe’s most promising research programs is STX-1150, which uses the ELXR platform to address high cholesterol levels by targeting the PCSK9 gene in the liver.
PCSK9 plays a major role in regulating low-density lipoprotein cholesterol, commonly known as LDL cholesterol.
In preclinical studies involving non-human primates, therapeutic dosing of less than 1 mg per kilogram successfully reduced LDL cholesterol levels. The gene silencing effect was both potent and long-lasting, suggesting that this therapy could offer a powerful alternative to existing cholesterol-lowering treatments.
Such advances could benefit individuals at high risk of Atherosclerotic Cardiovascular Disease, a major cause of heart attacks and strokes worldwide.
The STX-1200 Program
Another promising development from Scribe is the STX-1200 program.
This therapy uses the XE gene-editing platform to directly target the Lipoprotein(a) gene.
Elevated Lipoprotein(a) levels are linked to increased cardiovascular risk, but treatment options for reducing these levels remain limited.
In preclinical models, the STX-1200 program demonstrated greater than 90% knockdown of Lipoprotein(a) levels, a remarkable achievement that highlights the potential of precision genome editing.
Delivery Strategies for Gene Editing
Another key aspect of developing successful CRISPR therapies is delivering the gene-editing tools safely into the body.
Scribe has explored multiple strategies for in vivo delivery, including:
- Adeno-associated virus
- Lipid Nanoparticles
Both technologies have become important tools in modern biotechnology. They allow therapeutic molecules to reach specific tissues within the body, enabling scientists to target disease at the molecular level.
Insights from Dr. Aarif Khakoo
During the forum, Aarif Khakoo will share insights into the technical challenges and opportunities associated with developing these therapies.
His presentation will highlight:
- The scientific strategy behind Scribe’s CRISPR platforms
- The latest preclinical data supporting ongoing programs
- The next steps toward clinical evaluation of these therapies
Attendees will also have the chance to participate in a Q&A session, offering an opportunity to engage directly with the speaker and discuss the future of genome editing.
Event Agenda
The evening will include both networking opportunities and scientific discussion.
5:00 PM – 6:00 PM | Networking, Appetizers, and Drinks
Guests can connect with local bioscience professionals while enjoying appetizers and refreshments.
6:00 PM – 7:00 PM | Presentation
The scientific presentation will be delivered by the guest speaker and followed by an interactive Q&A session.
Event Details
The forum will take place on:
Tuesday, March 31
5:00 PM (GMT-07:00)
at The Alexandria at San Carlos.
A Glimpse into the Future of Medicine
The BioScience Forum Presents: Precision CRISPR Therapies provides an exciting opportunity to explore how genome editing is transforming modern healthcare.
With the potential to treat complex conditions such as cardiovascular disease, genetic disorders, and neurological illnesses, CRISPR-based technologies are paving the way for a new era of precision medicine.
By bringing together scientists, professionals, and innovators, events like this help foster collaboration and inspire the next generation of breakthroughs in biotechnology.
For those passionate about the future of science and medicine, this forum promises an evening filled with knowledge, inspiration, and meaningful connections.
See other interesting events in San Carlos. You may also check the main calendar for the dates of these, or to save them on your personal calendar.
About San Carlos
About Mark and Viv
Mark Martinho and Viv Kelvin are the owners of Vabrato Real Estate
